Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lonitoclax - Lomond Therapeutics

Next Previous
Drug Profile

Lonitoclax - Lomond Therapeutics

Alternative Names: ZE50-0134; Eiletoclax-Lomond Therapeutics

Latest Information Update: 17 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eilean Therapeutics
  • Class Amides; Anilides; Antineoplastics; Benzene derivatives; Chlorobenzenes; Isoquinolines; Ketones; Methyl ethers; Morpholines; Phenols; Phenyl ethers; Pyrroles; Small molecules; Toluenes
  • Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Lymphoma

Most Recent Events

  • 17 Mar 2026 Chemical structure information added.
  • 26 Dec 2025 Lomond Therapeutics plans a phase I trial for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) (PO, Capsule) in January 2026 (NCT07303660)
  • 06 Dec 2025 Interim adverse events, pharmacodynamic and pharmacokinetics data from a phase I trial in healthy volunteers presented at the full 67th American Society of Hematology Annual Meeting and Exposition (ASH 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top